44 results about "Pbsc mobilization" patented technology

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

A method for haematopoietic stem and / or progenitor cell (HSPC) transplantation in a subject in need thereof, comprising the steps: (a) administering one or more HSPC mobiliser to the subject to mobilise the subject's endogenous HSPCs; and (b) administering a population of HSPCs to the subject.

The invention discloses a system and a device for measuring the cardiopulmonary endurance of an adult, and relates to the technical field of cardiopulmonary endurance measurement. The system comprises a power vehicle, a heart rate acquisition module, a data processing module, a motion control and voice guide module, a load regulation and control module, a result output and data management module, a safety monitoring and stopping module and a user interaction module, and the power vehicle comprises a positioning base, a supporting seat, a vehicle frame, a counting and power utilization mechanism and a measurement and power recovery mechanism. A stable and controllable physical exercise platform and an adjustable load system are provided, a heart rate collection module collects heart rate data of a subject in the resting and exercise process in real time, and the heart rate data serve as a VOmax estimation core basis. And data of more dimensions can be incorporated during formula calculation of the maximum oxygen uptake, so that the effect is better.

To provide recombinant polyclonal proteins and use methods thereof.SOLUTION: Provided herein is a composition comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells or plasmablasts. Methods for using the RPPs are also provided. The RPPs are recombinant, and their sequences are derived from peripheral blood plasma cells or plasmablasts. The peripheral blood plasma cells or plasmablasts are mobilized by, e.g., a vaccine administered to a donor, and the peripheral blood plasma cells or plasmablasts are specifically separated from other peripheral blood cells. The peripheral blood cells can come from any mammal, for example a mouse, a rat, a human, a monkey, a horse, or a cow.SELECTED DRAWING: None

The present invention provides a personalized rehabilitation training method and system based on state monitoring, which relates to the field of rehabilitation training technology. The method includes: obtaining electromyographic amplitude, root mean square, and spectrum median, calculating the rate of change, monitoring muscle fiber mobilization, blood oxygen, lactate metabolism, and heart rate variability, extracting the rate of change of joint angles and moment of inertia, and obtaining a training load reference value. In the present invention, by real-time monitoring and analysis of multiple physiological parameters including electromyographic signals, blood oxygen saturation, and heart rate variability, an accurate training load reference value is established to improve the accuracy of neuromuscular coordination assessment. By comparing the rate of change of electromyographic signals in short and long time windows, the training load is accurately adjusted to reduce fatigue risk. By real-time adjustment of the rehabilitation robot's motion trajectory and optimization of the training rhythm, it is ensured that the training intensity matches the individual's metabolic capacity, and dynamic matching and personalized adjustment of the training plan are achieved, effectively improving the safety and effectiveness of training.

Provided herein is a bioreactor system, including a cell growth platform having a hydrogel arranged thereon, at least one first cell received on and / or in the hydrogel, a flow channel configured to receive a flow of a liquid therethrough, a separator arranged between the cell growth platform and the flow channel and having a first surface that faces the cell growth platform and a second surface in fluid communication with the flow channel, and at least one second cell received on the separator.

The present invention relates to a combination therapy and combination product for mobilizing large numbers of hematopoietic stem cells in the blood, comprising substance P and AMD3100 or a pharmaceutically acceptable salt thereof; a method for collecting large numbers of mobilized hematopoietic stem cells, comprising a step of separating a blood fraction containing mobilized hematopoietic stem cells from peripheral blood obtained from an individual to whom substance P and AMD3100 or a pharmaceutically acceptable salt thereof have been sequentially administered; and the use of a formulation comprising substance P and AMD3100 or a pharmaceutically acceptable salt thereof for mobilizing large numbers of hematopoietic stem cells in the blood.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

The present application relates to the field of biological medicine, in particular to a tumor treatment platform based on endogenous and exogenous zinc overload strategy, a preparation method and application. For the treatment platform, it comprises an acid-sensitive carrier, zinc ions and a sound-sensitive organic ligand; the sound-sensitive organic ligand can generate reactive oxygen under ultrasonic irradiation; the sound-sensitive organic ligand and the zinc ions are connected by a coordination bond to form a metal-organic complex; and the metal-organic complex is loaded on the acid-sensitive carrier. The present application proposes a tumor treatment strategy of "endogenous-exogenous synergy", combines "exogenous Zn 2+ " delivery with "endogenous Zn 2+ " mobilization, successfully induces "Zn 2+ overload" in cells through the synergistic effect of the two, realizes the precise, efficient and controllable induction of local Zn 2+ overload in tumors, and improves the effectiveness of pyroptosis. Through the present application, the limitations of traditional methods in controllability, efficacy and safety are overcome.

Disclosed herein are methods of mobilizing hematopoietic stem and progenitor cells (HSPC) in a subject in need thereof, the methods include administering one or both of (1) an inhibitor of the polymerization of hemoglobin S and (2) a P-selectin or E-selectin inhibitor, prior to administering a hematopoietic stem cell mobilizing agent.

A method of mobilizing hematopoietic precursor cells from the bone marrow to the peripheral blood of a subject is provided. The method comprising (a) administering to the subject an effective amount of natalizumab; and (b) administering to the subject an effective amount of a CXCR4 inhibitor, wherein step (b) is effected at least 48 hours following step (a). Also provided are uses of such mobilization procedures in cell collection and in treatment.

A method of mobilizing CD34 + cells in a subject suffering from sickle cell disease (SCD) is provided. The method comprises the following steps: a therapeutically effective amount of CXCR4 inhibitory peptide shown as SEQ ID NO: 1 and a therapeutically effective amount of natazumab are applied to a subject, and the natazumab and the CXCR4 inhibitory peptide are sequentially applied. Also provided is the use of mobilized cells for subsequent treatment of SCD in gene therapy.

Means, methods, and compositions of matter for accelerating hematopoiesis and / or stem cell engraftment through induction of senolysis and / or deactivation of senescent cells. Senolytic agents can be administered together with hematopoietic growth factors. Resistance to stem cell mobilization can be accomplished by removal of senescent cells through senolytic and / or senescence inactivating approaches.

This invention relates to methods for treatment of diseases of aging including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and / or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition for treating thalassemia and application thereof. The invention provides a pharmaceutical composition for treating thalassemia, which comprises: (a) a cell population containing a first type of cells and a second type of cells, the cell population can be used for differentiating to generate red blood cells, target loci of the first type of cells are edited to increase red blood cells expressing functional hemoglobin generated by differentiation of the cell population, and target loci of the second type of cells are edited to generate target loci of the second type of cells; the target gene loci of the second type of cells are not edited; (b) a mobilizing agent. The medicine composition can achieve the effect of treating thalassemia through cell transplantation without removing marrow, and the clinical treatment risk of a patient is reduced.

The invention designs a novel double-target peptide agonist targeting peripheral Kappa and Mu opioid receptors or pharmaceutically acceptable salts of the double-target peptide agonist, namely, chimeric peptides MKOP001 and MKOP002 are newly constructed on the basis of a DN-9 and dynorphin efficient analogue [des-Arg7] Dyn A (1-11)-NH2 sequence. An in-vitro calcium mobilization experiment and an acute analgesic experiment show that the brand new peptide agonists MKOP001 and MKOP002 can simultaneously activate Kappa and Mu opioid receptors and generate efficient analgesic activity. In addition, further research shows that both the MKOP001 and the MKOP002 can generate a remarkable itching relieving effect. Therefore, the peripheral restrictive Kappa and Mu opioid receptor double-target peptide molecules MKOP001 and MKOP002 or pharmaceutically acceptable salts thereof have very high application value in the aspect of preparing high-efficiency and low-side-effect analgesic or antipruritic drugs.

The present invention relates to methods and compositions for mobilizing cells in a subject by blocking CXCR4, β-adrenergic receptors, GPCRs, or any combination thereof. In some embodiments, the cells are stem cells. In some embodiments, the cells are immune cells.

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron / systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and / or improvement of cognitive functions in a subject in need thereof.

The invention provides a mouse bone marrow mesenchymal stem cell targeting peptide G15. The amino acid sequence of the targeting peptide G15 is as follows: Gly Val Ala Leu Gly Asp Asn Leu Ile Leu Leu Leu Asp Ser Gly. The drug carrier can be applied to recruitment and mobilization of in-vivo mesenchymal stem cells in injury-related diseases, and can be combined with the drug carrier to target the mesenchymal stem cells to deliver a specific drug to promote directional differentiation of the in-vivo mesenchymal stem cells so as to achieve a repair level. The invention solves the problems of low survival rate, biocompatibility and the like of in-vitro transplanted bone marrow mesenchymal stem cells, and provides a new thought for targeted therapy of small molecular drug targeted mesenchymal stem cells.

The invention relates to the technical field of biological medicine, and discloses application of paeoniflorin in preparation of medicine for preventing or treating acute graft versus host disease. The invention can promote hematopoietic recovery to regulate immune homeostasis. The donor hematopoietic stem cells are mobilized, glycometabolism, fatty acid metabolism and amino acid metabolism pathways of the hematopoietic stem cells are activated in a targeted manner, the activity of the transplanted hematopoietic stem cells is enhanced, and hematopoietic reconstruction is accelerated. The application disclosed by the invention can play a role in preventing or treating aGVHD by inhibiting amplification and activation of donor T cells, inhibiting release of inflammatory cytokines / chemotactic factors, improving the level of anti-inflammatory cytokines, relieving intestinal injury, balancing intestinal flora and other mechanisms.

The present disclosure provides therapeutic agents comprising VLA-4 (a4b1) and a4b?inhibiting agents defined herein. Methods of using the therapeutic agents are also provided. The present disclosure further provides combinations of a VLA-4 inhibitor and one or more agents which interact with a chemokine receptor or chemokine receptors, and methods of use thereof. In some embodiments, the disclosed combinations may be used in a method of mobilizing hematopoietic stem cells. In some embodiments, the disclosed methods may be used in the treatment of a condition that requires the collection of hematopoietic stem cells for transfusions or in chemotherapy. The present disclosure further provides methods of treating a patient comprising administering an agent which interacts with a chemokine such as G-CSF, plerixafor, BL-8040 (Motixafortide), or Crop and VLA-4 inhibitors.

The present invention relates to a method and composition for mobilizing cells from a subject by blocking CXCR4, beta-adrenergic receptors, GPCRs, or any combination thereof. In some embodiments, the cells are hematopoietic stem cells. In some embodiments, the method further comprises the administration of G-CSF. The present invention also relates to a treatment method, a method for qualifying a subject for treatment, and a method for preparing a subject for treatment by blocking CXCR4, beta-adrenergic receptors, GPCRs, or any combination thereof. In some embodiments, the cells are hematopoietic stem cells. In some embodiments, the treatment is for cancer. In some embodiments, CXCR4 is GPC-100. In some embodiments, the method further comprises the administration of G-CSF.

This invention describes new methods for the mobilization of human cells such as hematopoietic stem cells in bone marrow, and the subsequent collection of such cells from the peripheral blood of deceased donors. These methods produce quantities of hematopoietic stem cells that can be used in a multitude of possible applications without harming the deceased donor or the recovery of the deceased donor's organs for solid organ transplantation. The methods involve the administration of one or more mobilizing agents to mobilize bone marrow cells into the peripheral blood cells followed by the collection of cells via apheresis.

The invention relates to a memory-enhancing NK cell (EM-NK) culture medium and application thereof. The synergistic memory type NK cell (EM-NK) culture medium comprises a cell factor and antibody combination and mobilized peripheral blood plasma. According to the invention, the plasma component of the mobilized PBMC is added into a culture system and contains bioactive substances such as various cytokines and exosomes, so that the proliferation and activity enabling of cells are facilitated, and the stability and effectiveness in the preparation process are kept. Meanwhile, due to the fact that a specific cell factor and antibody combination is added into the culture medium, the purity of the obtained synergistic memory type NK cells is obviously improved, and meanwhile the killing rate is also obviously improved.

The present invention provides improved devices for biopsy, aspiration, stem cell acquisition, and methods of using the same. The devices balance aspiration with concurrent infusion to manage changes in pressure at the site of biopsy. The present invention can be adapted for any biopsy, aspiration, or cell harvest procedure, including adipose tissue aspiration and bone marrow aspiration (BMA). In particular, the present invention limits patient pain, prevents blood contamination, and increases cell mobilization, such as improved stem cell yields with intraosseous (10) pharmacological mobilization of stem cells during a BMA procedure, and with improved stem cell yields using pharmacological mobilization of stem cells from fat. The pharmacological mobilization of cells allows the harvest of cells from a biopsy many fold larger than existing methods.

The present invention has found that soluble P-selectin (sP-sel) can interfere with the interaction between stem cells and the niche and, thus, mobilize stem cells from the bone marrow. Accordingly, mobilizing stem cells with sP-sel can treat an individual in need of one or more of tissue preservation, repair, or regeneration or neovascularization in an individual.

The present disclosure is directed to a method of activation and expansion of adult non-activated hematopoietic stem and progenitor cells (HSPCs). The present disclosure reveals that Fli-1 activity is essential during regenerative hematopoiesis. Fli-1 directs activation programs while manipulating cellular sensory and output machineries, enabling HSPCs co-adoptability with a stimulated vascular niche. Applying FLI-1 transient modified-mRNA transduction into lethargic adult human mobilized HSPCs, enables their niche-mediated expansion and superior engraftment capacities. The present disclosure provides a population of regenerated and expanded adult hematopoietic stem and progenitor cells (HSPCs). The present disclosure also provides methods of treating a subject in need of activated and expanded adult HSPCs by administering the regenerated and expanded HSPCs to the subject.

The invention discloses a PBSC and PRP mixed product obtaining method and system based on synchronous collection, and the method comprises the steps: collecting basic information of a patient, treatment appeals and target specifications of a mixed product, selecting adaptive blood cell separation equipment and a sterile pipeline under the condition that a mobilizing agent is not used, and carrying out the collection of the mixed product; and a closed loop circulation system is constructed, and preparation setting is completed for synchronous collection of PBSC and PRP mixed products. After the program is started, blood components and fluid-physiological data are collected in real time through the sensing module and transmitted to the control unit. A multi-target control model is constructed based on improved particle swarm optimization, and parameters such as the centrifugal rotating speed are adjusted every 2 seconds under the constraint that component concentration reaches the standard and impurity residues meet the standard. After the peripheral blood is centrifuged and layered, the PBSC and the PRP are synchronously mixed, and red blood cells and redundant plasma are transfused back. Parameters are compared in real time to calculate deviation, and iteration adjustment is carried out when the threshold value exceeds; if the physiological parameters are abnormal, the flow rate is adjusted or an alarm is given, collection and quality inspection are terminated after the product reaches the standard, and if the product is qualified, a target mixed product is obtained. And the preparation safety and reliability are improved.

The invention discloses a blood use priority management system and a supply and demand balance implementation method based on a medical system. The system adopts a layered architecture design, and realizes blood resource allocation, priority blood use whole-process management, emergency blood donation mobilization and multi-system data intercommunication by integrating business system data of a medical member unit and a blood collection and supply mechanism; according to the implementation method, a closed-loop management system of appointment-recruitment-collection-supply is constructed through mechanisms such as dynamic quota regulation and control, accurate cashing of preferential blood utilization rights and intellectual blood donor recruitment linkage, the blood resource utilization efficiency is improved, the blood donation behavior is stimulated, and finally the dynamic balance of blood supply and demand is achieved. The blood resource allocation can be effectively optimized, the first-aid blood use and priority blood use requirements are guaranteed, and the intelligent level of regional blood management is improved.